The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in September 2022. 
A major focus of this issue is combinations of inhibitors of PD-(L)1 and novel immuno-oncology mechanisms.

You can also listen to our podcast that accompanies this edition in which Jacob Plieth talks through some of the highlights with Bertrand Delsuc, publisher of BioTech Radar.



Understand the challenges China-based developers face when trying to get anything approved in the US
Delve into clinical trial successes and failures across a variety of tumour types
Explore Merck and others’ efforts to maintain patent exclusivity
Know what lies ahead, with the possibility of new launches in the US and EU